P53 Antibody; Is it an Indicator of Dedifferentiated Thyroid Cancer?
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Cumhuriyet University
- Enrollment
- 199
- Locations
- 1
- Primary Endpoint
- There was not any risk for patients.
Study Overview
Brief Summary
In clinical practise patients with negative radioiodine scan with positive tyhroglobulin is considered as radioiodine resistant or in another words in the process of dedifferentiation. The aim of the present study was to search a simple blood test that could lead to early identification of patients with dedifferentiation. In this respect, we investigate whether the serum level of anti-p53 antibody has the diagnostic value in the follow-up of patients with high levels of thyroglobulin (tg) and negative I-131 scan.
Detailed Description
In the present study enrolled were 171 patients with mean age of 47.7±13.5 yrs (range; 16-80yrs) and 28 healthy subjects with an age range of 18-52 yrs (mean: 36.0±9.8 yrs). 134 (78.4%) patients were female and 37 (21.6%) patients were male.
Study Design
- Study Type
- Observational
- Observational Model
- Case Control
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 16 Years to 80 Years (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients who were diagnosed with DTC
- •Treated with total and/or near-total thyroidectomy
- •Referred for I-131 ablation therapy or low dose I-131 whole body scan (WBS)
- •Between December 2010 and January 2013.
Exclusion Criteria
- •Dose 131-I given in another hospital
- •Radioiodine treatment more than one year after thyroidectomy.
Outcomes
Primary Outcomes
There was not any risk for patients.
Time Frame: with in the first 8-10 months after surgery
Secondary Outcomes
No secondary outcomes reported
Investigators
Zekiye HASBEK, M.D., Assistant Professor
Cumhuriyet University, School of Medicine, Department of Nuclear Medicine
Cumhuriyet University